Abstract:Lara Kujtan 1^ , Janakiraman Subramanian 2 1 Richard and Annette Bloch Cancer Center, University of Missouri at Kansas City, Kansas City, MO, USA; 2 Inova Schar Cancer Institute, Fairfax, VA, USA ^ ORCID: 0000-0001-9758-1777. Comment on: Camidge DR, Barlesi F, Goldman JW, et al . Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol 2023;41:1105-15. Keywords: Lung cancer; epidermal growth factor receptor (EGFR); MET; telisotuzumab vedotin Submitted May 02, 2023. Accepted for publication Jul 07, 2023. Published online Jul 28, 2023. doi: 10.21037/tlcr-23-288 The hepatocyte growth factor and c-Met receptor tyrosine kinase axis plays a key role in normal biological functions including embryogenesis, cell proliferation, and tissue regeneration (1). Several malignancies, including lung cancer, exploit abnormal activation of c-Met for carcinogenesis. Early efforts to target c-Met in lung cancer were unsuccessful but that has changed recently with the development of MET tyrosine kinase inhibitors (TKI) targeting MET exon 14 skipping (METex14) mutation (2-4). The MET TKIs capmatinib and tepotinib are FDA-approved in the United States for patients with METex14 mutation-positive non-small cell lung cancer (NSCLC), and approved by the EMA in Europe as a second-line treatment option. Savolitinib is approved in the second-line setting in China. Apart from MET TKIs, amivantamab [a bispecific antibody targeting epidermal growth factor receptor (EGFR) and MET] and Sym015 (a mixture of two humanized monoclonal antibodies that degrade MET receptor by binding to its extracellular domain), have shown activity against METex14 positive NSCLC (5,6) ( Figure 1 ). These MET TKIs and antibodies have shown activity against both de-novo and acquired MET -amplification in NSCLC but further studies are needed to delineate the role of these agents in treating patients with MET -amplified NSCLC (reviewed in Remon et al. , 2023) (7). Treatment with MET TKIs currently benefits only a small proportion (4%) of patients with NSCLC that harbor METex14 mutation. However, c-Met overexpression is far more common than METex14 and MET amplification in patients with NSCLC at 30–70% (1). Previous efforts to target the hepatocyte growth factor (HGF) and c-Met axis using monoclonal antibodies proved to be unsuccessful (8-10). Similarly small molecule kinase inhibitors have not been effective against MET overexpressing tumors. The presence of c-Met overexpression does not indicate activation of the MET pathway and that may explain the lack of benefit. Advances in antibody design now allow targeted delivery of cytotoxic agents to the tumor cells and these antibody-drug conjugates (ADC) present a novel mechanism to target cancer cells. They target specific surface proteins expressed on cancer cells regardless of their role in cell signaling and survival. Telisotuzumab vedotin (Teliso-V) is an ADC with a c-Met targeting humanized monoclonal antibody combined with the microtubule inhibitor monomethyl auristatin by a cleavable valine-citrulline peptide linker. The combination has approximately three molecules of monomethyl auristatin per antibody. In preclinical studies, Teliso-V is active against cancer cells overexpressing c-Met or with MET amplification and its activity is independent of the cell's MET pathway activity (11). The cytotoxic activity of Teliso-V appears to be dependent on the cell surface expression of c-Met, and tumor cells with higher levels of c-Met expression are more sensitive to Teliso-V. A subsequent first in human trial reported favorable safety and promising activity for single agent Teliso-V in c-Met expressing NSCLC (12). However, studies in squamous NSCLC have shown limited response and severe toxicity with grade 5 pneumonitis (13,14). In this phase Ib study by Camidge and colleagues evaluated the safety and efficacy of the combination of Teliso-V with the EGFR TKI erlotinib in patients with c-Met expressing advanced NSCLC in whom no other approved therapies were available (15). Archival tissue was required to confirm c-Met overexpression, MET exon 14 mutation, or MET amplification. c-Met-overexpression in this study was defined as histology (H)-score of 150 or greater. The study primarily focused on patients (n=31) with activating EGFR TK mutations (EGFRm) who had progressed on EGFR TKIs. Patients with activating EGFRm can develop resistance to EGFR TKIs due to on-target EGFR mutations, off-target bypass pathway signaling including MET amplification in 15–30% or lineage transformation (16,17). Combining Teliso-V with erlotinib can target MET pathway-activated tumors as well as tumor -Abstract Truncated-

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma

Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial.

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial

Abstract CT193: Tepotinib + gefitinib vs chemotherapy in<i>MET-</i>amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study

A Multi-Center Phase II Study of Toripalimab with Chemotherapy in Patients with EGFR Mutant Advanced NSCLC Patients Resistant to EGFR TKIs: Efficacy and Biomarker Analysis.

1263P Tislelizumab + Chemotherapy Vs Chemotherapy Alone As First-Line Treatment for Locally Advanced/metastatic Nonsquamous NSCLC

Phase II Study of Tepotinib + Gefitinib (TEP+GEF) in MET-positive (met+)/epidermal Growth Factor Receptor (Egfr)-Mutant (MT) Non-Small Cell Lung Cancer (NSCLC).

OA14 Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (Egfr)-Mutant Non-Small Cell Lung Cancer

Tepotinib + Gefitinib (TEP+GEF) in MET+/epidermal Growth Factor Receptor (Egfr)-Mutant Non-Small Lung Cancer (NSCLC): Phase II Data

Tislelizumab plus chemotherapy for patients with EGFR -mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation

BGB-A317-212: A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy and Safety of Tislelizumab in Combination with Lenvatinib in Patients with Selected Solid Tumors.

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer

Tislelizumab Combined with Nab-Paclitaxel Single-Agent Chemotherapy Plus Bevacizumab for Patients with EGFR-TKIs-resistant Advanced NSCLC with ECOG PS 0-2.

Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR -mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.

A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR-Mutated MET-Amplified Advanced Non-Small-Cell Lung Cancer

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer